Synthesis and Structure of Dimeric Copper (I) Complex from Bis[(2,2’)-dimethyl 2,2’-(1,10-phenanthroline-2,9-diyl) bis(methan-1-yl-1-ylidene)-bis(hydrazinecarbo dithioate)]

Md. Arifuzzaman, Tasneem A. Siddiquee, Mohammad R. Karim, Aminul H. Mirza, Mohamad A. Ali

Department of Chemistry, Faculty of Science, University of Brunei Darussalam, Gadong, Malaysia.
Department of Chemistry, Tennessee State University, Nashville, USA.

DOI: 10.4236/csta.2013.24022                

Abstract

Metal complex, bis[(2,2’)-dimethyl 2,2’-(1,10-phenanthrline-2,9-diyl)bis(methan-1-yl-1-ylidene)-bis(hydrazinecarrbo dithioate)copper(I)], was synthesized from the reaction of Schiff base, (2,2’)-dimethyl 2,2’-(1,10-phenanthroline-2,9-diyl)bis(methan-1-yl-1-ylidene)-bis(hydrazinecarbo dithioate) and CuCl₂ at reflux condition in methanol. The copper centers of the complex appear to be reduced. This probably was facilitated by in situ oxidative formation of disulfide bond at the uncomplexed ligand moieties. Single crystal X-ray diffraction analysis reveals the distorted tetrahedral geometry around the copper centers. This compound crystallizes in the triclinic space group, P-1 with crystallographic parameters: a = 10.006(3) ?, b = 13.272(3) ?, c = 22.123(6) ?, α = 85.656(6)°, β = 81.656(6)°, γ = 73.097(5)°, μ = 1.223 mm^-1 , V = 2779.5(13) ?3, Z = 2, Dc = 1.437 Mg/m³, T = 293 (2) K.

Keywords

Schiff Base; Copper Complex; Metal Complex; Phenanthroline; Hydrazinecarbo Dithioate, X-Ray Diffraction

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	J. Reedijk, “Comprehensive Coordination Chemistry, Vol. 2,” In: G. Wilkinson, R. D. Dillard and J. A. McCleverty, Eds., Comprehensive Coordination Chemistry, Pergamon, Oxford, 1987, p. 73.
[2]	S. Kumar, D. N. Dhar and P. N. Saxena, “Applications of Metal Complexes of Schiff Bases—A Review,” Journal of Scientific and Industrial Research, Vol. 68, No. 3, 2009, pp. 181-187.
[3]	Y. Shen and B. P. Sullivan, “Versatile Preparative Route to 5-Substituted-1,10-phenanthroline Ligands via 1,10-Phenanthroline-5,6-epoxide,” Inorganic Chemistry, Vol. 34, No. 25, 1995, pp. 6235-6236. http://dx.doi.org/10.1021/ic00129a003
[4]	Md. A. Masood and P. S. Zacharias, “Electrochemical Reversibility of the CuI-Cu0 Couple in Bis[2,9-di(o-substituted phenyl)-1,10-phenanthroline]-copper(I) Complexes. Stability of the Corresponding Copper(0) Species,” Journal of the Chemical Society, Dalton Transactions, No. 1, 1991, pp. 111-114. http://dx.doi.org/10.1039/dt9910000111
[5]	A. Zaid, J.-S. Sun, C.-H. Nguyen, E. Bisagni, T. Garestier, D. S. Grierson and R. Zain, “Triple-Helix Directed Cleavage of Double-Stranded DNA by Benzoquinoquinoxaline-1,10-phenanthroline Conjugates,” ChemBioChem, Vol. 5, No. 11, 2004, pp. 1550-1557. http://dx.doi.org/10.1002/cbic.200400074
[6]	H. Amiri, N. Nekhotiaeva, J.-S. Sun, C.-H. Nguyen, D. S. Grierson, L. Good and R. Zain, “Benzoquinoquinoxaline Derivatives Stabilize and Cleave H-DNA and Repress Transcription Downstream of a Triplex-forming Sequence,” Journal of Molecular Biology, Vol. 35, No. 4, 2005, pp. 776-783. http://dx.doi.org/10.1016/j.jmb.2005.03.044
[7]	T. K. Goswami, S. Gadadhar, A. A. Karande and A. R. Chakravarty, “Photocytotoxic Ferrocene-Appended (l-Tyrosine)copper(II) Complexes of Phenanthroline Bases,” Polyhedron, Vol. 52, 2013, pp. 1287-1298. http://dx.doi.org/10.1016/j.poly.2012.06.018
[8]	M. A. Masood and D. J. Hodgson, “Synthesis and Characterization of the Multidentate Ligand 2,9-Bis(N-pyrazolylmethyl)-1,10-phenanthroline (bpmp) and Its Copper(I) and Copper(II) Complexes,” Inorganic Chemistry, Vol. 32, No. 22, 1993, pp. 4839-4844. http://dx.doi.org/10.1021/ic00074a031
[9]	E. M. Bavin, R. J. W. Reea, J. M. Robson, M. Seiler, D. E. Seymour and D. Suddaby, “The Tuberculostatic Activity of Some Thiosemicarbazones,” Journal of Pharmacy and Pharmacology, Vol. 2, No. 1, 1950, pp. 764-772. http://dx.doi.org/10.1111/j.2042-7158.1950.tb12999.x
[10]	G. A. Kune, “To-Day’s Drug: Methisazone,” British Medical Journal, Vol. 2, 1964, p. 621.
[11]	A. C. Sartorelli and B. A. Booth, “Inhibition of the Growth of Sarcoma 180 Ascites Cells by Combinations of Inhibitors of Nucleic Acid Biosynthesis and the Cupric Chelate of Kethoxal Bis-(thiosemicarbazone),” Cancer Research, Vol. 27, No. 9, 1967, pp. 1614-1619.
[12]	C. M. Nutting, C. M. L. Herpan and A. B. Miah, “Phase II Study of 3-AP Triapine in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,” Annals of Oncology, Vol. 20, No. 7, 2009, pp. 1275-1279. http://dx.doi.org/10.1093/annonc/mdn775
[13]	S. H. N. Moorthy, M. F. S. A. Cerqueira, J. Ramos and A. Farnandes, “Aryl- and Heteroaryl-Thiosemicarbazone Derivatives and Their Metal Complexes: A Pharmacological Template,” Anticancer Drug Discovery, Vol. 8, No. 2, 2013, pp. 148-152
[14]	B. Ma, B. C. Goh and E. H. Tan, “A Multicenter Phase II trial of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (3-AP, Triapine®) and Gemcitabine in Advanced Non-Small-Cell Lung Cancer with Pharmacokinetic Evaluation Using Peripheral Blood Mononuclear Cells,” Investigational New Drugs, Vol. 26, No. 2, 2008, pp. 169-173. http://dx.doi.org/10.1007/s10637-007-9085-0
[15]	Md. Arifuzzaman, M. R. Karim, T. A. Siddiquee, A. H. Mirza and M. A. Ali, “Synthesis and Characterization of New Schiff Bases Formed by Condensation of 2,9-Phenathroline-1,10-dialdehyde with Sulfur-Containing Amines,” International Journal of Organic Chemistry, Vol. 3, No. 1, 2013, pp. 81-86.
[16]	G. M. Sheldrick, “Program for the Solution and Refinement of Crystal Structures,” University of Gottingen, Gottingen, 1997.
[17]	CrystalClear: Rigaku Corporation, “CrystalClear Software User’s Guide, Molecular Structure Corporation,” Rigaku Corporation, 1999, pp. 1718-1725.
[18]	Crystal Crystallography, “WinGX Suite for Small-Molecule Single-Crystal Crystallography,” Journal of Applied Crystallography, Vol. 32, 1999, pp. 837-838. http://dx.doi.org/10.1107/S0021889899006020
[19]	S. K. Sahoo, N. Khatun, A. Gogoi, A. Deb and B. K. Patel, “Cu(II) Catalysed Chemoselective Oxidative Transformation of Thiourea to Thioamidoguanidine/2-aminobenzothiazole,” RSC Advances, Vol. 3, No. 2, 2013, pp. 438-446.
[20]	A. Thapper, A. C. Rizzi, C. D. Brondino, A. G. Wedd, R. J. Pais, B. K. Maiti, I. Moura and S. R. Pauelta, “Copper-Substituted Forms of the Wild Type and C42A Variant of Rubredoxin,” Journal of Inorganic Biochemistry, Vol. 127, 2013, pp. 232-237.